Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones

Biochemical Pharmacology

Volumn 83, Issue 12, 2012, Pages 1623-1633

  Heffeter, Petra ^a,c,d   Pirker, Christine ^a   Kowol, Christian R ^b,c,d   Herrman, Gerrit ^e   Dornetshuber, Rita ^a,b   Miklos, Walter ^a   Jungwirth, Ute ^a,c,d   Koellensperger, Gunda ^e   Keppler, Bernhard K ^b,c,d   Berger, Walter ^a,c,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Research Platform Translational Cancer Therapy Research   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

ABC transporter; Glutathione; Multidrug resistance; Resistance; Thiosemicarbazones; Triapine

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ABC TRANSPORTER; ALPHA N HETEROCYCLIC THIOSEMICARBAZONE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CARMUSTINE; CHROMOSOME DEOXYRIBONUCLEIC ACID; CISPLATIN; DAUNORUBICIN; DNA; DOXORUBICIN; ETACRYNIC ACID; ETOPOSIDE; GALLIUM; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYDROXYUREA; KP 1089; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PACLITAXEL; TEMOZOLOMIDE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

ABCC1 GENE; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG MECHANISM; DRUG RESISTANCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; HETEROCYCLIC COMPOUNDS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; METHYLATION; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; THIOSEMICARBAZONES;

EID: 84860160506     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.03.004     Document Type: Article

References (39)

1. F.J. Giles, P.M. Fracasso, H.M. Kantarjian, J.E. Cortes, R.A. Brown, and S. Verstovsek Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia Leuk Res 27 2003 1077 1083
2. J.E. Karp, F.J. Giles, I. Gojo, L. Morris, J. Greer, and B. Johnson A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders Leuk Res 32 2008 71 77
3. S. Attia, J. Kolesar, M.R. Mahoney, H.C. Pitot, D. Laheru, and J. Heun A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas Invest New Drug 2008
4. B. Ma, B.C. Goh, E.H. Tan, K.C. Lam, R. Soo, and S.S. Leong A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine((R))) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells Invest New Drug 26 2008 169 173
5. J.J. Knox, S.J. Hotte, C. Kollmannsberger, E. Winquist, B. Fisher, and E.A. Eisenhauer Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161) Invest New Drug 25 2007 471 477
6. G. Rappa, A. Lorico, M.C. Liu, G.D. Kruh, A.H. Cory, and J.G. Cory Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase Biochem Pharmacol 54 1997 649 655
7. A.M. Traynor, J.W. Lee, G.K. Bayer, J.M. Tate, S.P. Thomas, and M. Mazurczak A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 Invest New Drug 28 2010 91 97
8. S. Attia, J. Kolesar, M.R. Mahoney, H.C. Pitot, D. Laheru, and J. Heun A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas Invest New Drug 26 2008 369 379
9. P. Heffeter, U. Jungwirth, M. Jakupec, C. Hartinger, M. Galanski, and L. Elbling Resistance against novel anticancer metal compounds: differences and similarities Drug Resist Update 11 2008 1 16
10. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 2006 219 234
11. C.R. Kowol, R. Berger, R. Eichinger, A. Roller, M.A. Jakupec, and P.P. Schmidt Gallium(III) and iron(III) complexes of alpha-N-heterocyclic thiosemicarbazones: synthesis, characterization, cytotoxicity, and interaction with ribonucleotide reductase J Med Chem 50 2007 1254 1265
12. C.R. Kowol, R. Trondl, P. Heffeter, V.B. Arion, M.A. Jakupec, and A. Roller Impact of metal coordination on cytotoxicity of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation J Med Chem 2009
13. V.B. Arion, M.A. Jakupec, M. Galanski, P. Unfried, and B.K. Keppler Synthesis, structure, spectroscopic and in vitro antitumour studies of a novel gallium(III) complex with 2-acetylpyridine (4)N-dimethylthiosemicarbazone J Inorg Biochem 91 2002 298 305
14. A. Korynevska, P. Heffeter, B. Matselyukh, L. Elbling, M. Micksche, and R. Stoika Mechanisms underlying the anticancer activities of the angucycline landomycin E Biochem Pharmacol 74 2007 1713 1726
15. P. Heffeter, M.A. Jakupec, W. Korner, P. Chiba, C. Pirker, and R. Dornetshuber Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24) Biochem Pharmacol 73 2007 1873 1886
16. D.W. Shen, C. Cardarelli, J. Hwang, M. Cornwell, N. Richert, and S. Ishii Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins J Biol Chem 261 1986 7762 7770
17. P. Heffeter, M. Pongratz, E. Steiner, P. Chiba, M.A. Jakupec, and L. Elbling Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H-indazole) ruthenate (III)] (FFC14A) J Pharmacol Exp Ther 312 2005 281 289
18. C. Pirker, M. Raidl, E. Steiner, L. Elbling, K. Holzmann, and S. Spiegl-Kreinecker Whole genome amplification for CGH analysis: linker-adapter PCR as the method of choice for difficult and limited samples Cytometry A 61 2004 26 34
19. C. Pirker, K. Holzmann, S. Spiegl-Kreinecker, L. Elbling, C. Thallinger, and H. Pehamberger Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes Melanoma Res 13 2003 483 492
20. C. Pirker, D. Lotsch, S. Spiegl-Kreinecker, F. Jantscher, H. Sutterluty, and M. Micksche Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465 Exp Dermatol 19 2010 1040 1047
21. R. Dornetshuber, P. Heffeter, M. Sulyok, R. Schumacher, P. Chiba, and S. Kopp Interactions between ABC-transport proteins and the secondary Fusarium metabolites enniatin and beauvericin Mol Nutr Food Res 53 2009 904 920
22. J. Wang, L.S. Tai, C.H. Tzang, W.F. Fong, X.Y. Guan, and M. Yang 1p31, 7q21 and 18q21 chromosomal aberrations and candidate genes in acquired vinblastine resistance of human cervical carcinoma KB cells Oncol Rep 19 2008 1155 1164
23. D.R. Duckett, and M.D. Cameron Metabolism considerations for kinase inhibitors in cancer treatment Expert Opin Drug Metab Toxicol 6 2010 1175 1193
24. S.F. Zhou, L.L. Wang, Y.M. Di, C.C. Xue, W. Duan, and C.G. Li Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development Curr Med Chem 15 2008 1981 2039
25. S.P. Cole, and R.G. Deeley Transport of glutathione and glutathione conjugates by MRP1 Trends Pharmacol Sci 27 2006 438 446
26. I. Akan, S. Akan, H. Akca, B. Savas, and T. Ozben Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine Cancer Cell Int 5 2005 22
27. Y. Chuman, Z.S. Chen, K. Seto, T. Sumizawa, T. Furukawa, and A. Tani Reversal of MRP-mediated vincristine resistance in KB cells by buthionine sulfoximine in combination with PAK-104P Cancer Lett 129 1998 69 76
28. W.H. Habig, and W.B. Jakoby Assays for differentiation of glutathione S-transferases Methods Enzymol 77 1981 398 405
29. E.A. Enyedy, M.F. Primik, C.R. Kowol, V.B. Arion, T. Kiss, and B.K. Keppler Interaction of Triapine and related thiosemicarbazones with iron(III)/(II) and gallium(III): a comparative solution equilibrium study Dalton Trans 40 2011 5895 5905
30. P.V. Bernhardt, P.C. Sharpe, M. Islam, D.B. Lovejoy, D.S. Kalinowski, and D.R. Richardson Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity J Med Chem 52 2009 407 415
31. X.B. Chang A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1 Cancer Metastasis Rev 26 2007 15 37
32. D. Keppler Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy Handb Exp Pharmacol 29 2011 9 32 3
33. J. Lutzky, M.B. Astor, R.N. Taub, M.A. Baker, K. Bhalla, and J.E. Gervasoni Jr. Role of glutathione and dependent enzymes in anthracycline- resistant HL60/AR cells Cancer Res 49 1989 4120 4125
34. R.M. Laberge, J. Karwatsky, M.C. Lincoln, M.L. Leimanis, and E. Georges Modulation of GSH levels in ABCC1 expressing tumor cells triggers apoptosis through oxidative stress Biochem Pharmacol 73 2007 1727 1737
35. T.R. Crenshaw, and J.G. Cory Overexpression of protein disulfide isomerase-like protein in a mouse leukemia L1210 cell line selected for resistance to 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone, a ribonucleotide reductase inhibitor Adv Enzyme Regul 42 2002 143 157
36. J.A. Ludwig, G. Szakacs, S.E. Martin, B.F. Chu, C. Cardarelli, and Z.E. Sauna Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer Cancer Res 66 2006 4808 4815
37. M.D. Hall, N.K. Salam, J.L. Hellawell, H.M. Fales, C.B. Kensler, and J.A. Ludwig Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells J Med Chem 52 2009 3191 3204
38. Y. Huang, P.E. Blower, C. Yang, C. Barbacioru, Z. Dai, and Y. Zhang Correlating gene expression with chemical scaffolds of cytotoxic agents: ellipticines as substrates and inhibitors of MDR1 Pharmacogenomics J 5 2005 112 125
39. C.P. Wu, S. Shukla, A.M. Calcagno, M.D. Hall, M.M. Gottesman, and S.V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol Cancer Ther 6 2007 3287 3296